OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Goldberg on the Investigation of VIC-1911 With/Without Sotorasib in KRAS G12C-Mutant NSCLC

July 21st 2023

Sarah Goldberg, MD, MPH, discusses the design and key objectives of an ongoing phase 1a/b study of VIC-1911 as a monotherapy and in combination with sotorasib in KRAS G12C–mutant non–small cell lung cancer.

Dr Johnson on ABBV-011 in Small Cell Lung Cancer

July 20th 2023

Melissa L. Johnson, MD, discusses the development of the seizure-related homolog protein 6–targeting antibody-drug conjugate ABBV-011 and outcomes with this agent in patients with small cell lung cancer.

Dr Halpern on Momelotinib in Myelofibrosis With Anemia

July 20th 2023

Anna B. Halpern, MD, discusses symptom control, transfusion independence, and spleen volume findings with the JAK and ACVR1 inhibitor momelotinib vs the JAK inhibitor ruxolitinib and danazol in patients with myelofibrosis with anemia.

Dr Erba on the FDA Approval of Quizartinib Plus Chemotherapy in FLT3-ITD–Positive AML

July 20th 2023

Harry P. Erba, MD, PhD, discusses the significance of the FDA approval of quizartinib in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Dr Danish on the Use of SCINTIX Radiation Technology in Metastatic Bone and Lung Tumors

July 20th 2023

Adnan F. Danish, MD, discusses the use of SCINTIX radiation technology in metastatic bone and lung tumors.

Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma

July 20th 2023

Nikhil C. Munshi, MD, discusses the implications of the findings from the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and the CAR T-cell therapy’s subsequent FDA approval for use in this patient population.

Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS

July 20th 2023

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Dr Galsky on the Efficacy of Adjuvant Nivolumab in the CheckMate 274 Trial in mUC

July 20th 2023

Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.

Dr Burke on Ongoing Investigations of Targeted Therapy Regimens in MCL

July 20th 2023

John M. Burke, MD, discusses several ongoing or upcoming investigations of targeted therapy in mantle cell lymphoma.

Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the Prostate

July 19th 2023

Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.

Dr Ahmed on the Rationale for Investigating Real-World Outcomes of Brexu-Cel in R/R MCL

July 19th 2023

Nausheen Ahmed, MD, discusses the rationale for investigating real-world outcomes of patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC

July 19th 2023

Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.

Dr Damodaran on the ELAINE-3 Trial in Patients With ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

July 19th 2023

Senthil Damodaran, MD, PhD, discusses the rationale for the phase 3 ELAINE-3 trial in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast Cancer

July 19th 2023

Michelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.

Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based Analyses

July 19th 2023

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Dr Hannan on the Advantages of Stereotactic Radiation in Primary and Locally Advanced RCC

July 19th 2023

Raquibul Hannan, MD, PhD, discusses the advantages of stereotactic radiation in primary or locally advanced renal cell carcinoma.

Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC

July 18th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

Dr Taieb on the Safety Proline of TAS-102/Bevacizumab in Refractory mCRC

July 18th 2023

Julien Taieb, MD, PhD, discusses the safety profile associated with trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer.

Dr Lowentritt on the Rationale for Investigating Real-World PSA Response to AR Inhibitors in mCSPC

July 18th 2023

Benjamin H. Lowentritt, MD, FACS, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen responses generated from second-generation androgen receptor inhibitors in patients with metastatic castration-sensitive prostate cancer.

Dr Zhang on the Potential Use of RNA Sequencing to Improve Treatment Selection in Advanced RCC

July 18th 2023

Tian Zhang, MD, MHS, discusses whether the use of RNA sequencing to identify biologic cluster assignment could improve first-line treatment selection in metastatic renal cell carcinoma.